Dr. Ian Pavord discusses new meta-analyses of dupilumab planned for ATS 2020.

Panagis Galiatsatos, MD, MHS, joins to discuss the underlying issues and potential solutions to COVID-19 patient disparities.

Discussing a would-be ARVO 2020 presentation examining the use of anterior chamber intracameral dexamethasone drug-delivery suspen for postoperative inflammation in patients undergoing vitreoretinal surgery.

Investigators from Saint Louis University discuss their recent study comparing GLP-1 receptor agonists with SGLT2 inhibitors.

Clinical investigator and allergist Jonathan Corren, MD, shares insight on the TSLP inhibitor.

Al Rizzo, MD, CMO of the American Lung Association, discusses some of the biggest challenges and questions raised on lung health during the coronavirus pandemic.

Amy S. Paller, MD, principal investigator of the phase 3 LIBERTY AD PEDS trial, discusses the add-on biologic's benefit for young patients and potential as a pediatrc allergic therapy.

Dr. Kaneko, a cardiac surgeon at Brigham and Women's Hospital, breaks down a trio of studies he was associated with from ACC.20, including a look into PLO FLOW TAVR, the July Effect, and alternative access TAVR.

The ORION-11 principal investigator highlights new LDL-C reduction findings and teases future research for the siRNA-targeting drug.